The anti-tumor effects of isoliensinine were significantly enhanced when combined with the AKT inhibitor AKTi-1/2, demonstrating a synergistic therapeutic strategy for cervical cancer treatment (70). This evidence concerns the gene AKT1 and cervical carcinoma.